CoChat

Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors.

Sullivan, Ryan J., Hong, David S., Tolcher, Anthony W., Patnaik, Amita, Shapiro, Geoffrey, Chmielowski, Bartosz, Ribas, Antoni, Brail, Les H., Roberts, Jennifer, Lee, Lucy, O'Connell, Brenda, Kutok, Jeffrey Lorne, Mahabhashyam, Suresh, Dansky Ullmann, Claudio, Postow, Michael A., Wolchok, Jedd D. · 2018 · Journal of Clinical Oncology
Cited by 58

The DOI matches its Crossref record.

Abstract

3013 Background: IPI-549 is a potential first-in-class, oral, selective PI3K-γ inhibitor that in preclinical studies reprograms macrophages from an immune-suppressive to an immune-activating phenotype and can overcome resistance to checkpoint inhibitors. Methods: Ph 1/1b study IPI-549-01 (NCT02637531) is evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunomodulatory activity of IPI-549 to determine its recommended Ph 2 dose (RP2D) and preliminary efficacy, as monotherapy and combined with nivolumab (nivo), in advanced solid tumor pts. Pre- and on-treatment blood samples were obtained for flow cytometry, gene expression, and serum analysis. Results: Initial combination dose-escalation results are reported. 31 pts (30 evaluable), median age 57 yrs and median 4 prior therapies (8 with prior anti PD-(L)1 therapy), received IPI-549 20, 30, and 40 mg QD + nivo 240 mg Q2W in a 6+6 design. IPI-549 PK/PD were unaffected by nivo. The MTD was not reached. Most treatment-emergent adverse events (TEAEs) were Gr 1-2. The most common (≥ 2 pts) treatment-related TEAEs included rash (23%); pruritus (10%); and nausea, anemia, ALT increase, AST increase, and pyrexia (6% each), with no treatment-related deaths. 2 DLTs each occurred at IPI-549 30 mg (Gr 3 rash) and 40 mg QD (Gr 3 rash; Gr 3 ALT/AST increase). 2 pts demonstrated partial responses at first assessment (8 wks): 1 with adrenocortical carcinoma and 1 with microsatellite-stable gallbladder carcinoma receiving IPI-549 30 and 40 mg QD, respectively. 40% of pts (n = 12) remained on study ≥ 12 wks and 6 pts were ongoing at the 05 Feb data cutoff. Based on safety + PK/PD data, the RP2D was IPI-549 40 mg QD + nivo 240 mg Q2W. On-treatment blood samples show evidence of immune activation and reduced immune suppression, including upregulation of IFNg-responsive factors, such as PD-L1 and CXCL9/10, and dose-dependent re-invigoration/proliferation of exhausted PD1+CD8+CD45RA- T cells, evidenced by Ki67 increases. Conclusions: IPI-549 + nivo demonstrates favorable tolerability, early signs of clinical activity, and evidence of immune modulation. Combination expansion cohorts are enrolling at the RP2D. Clinical trial information: NCT02637531.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2018.36.15_suppl.3013

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 58

Metadata

Authors
Sullivan, R. J., Hong, D. S., Tolcher, A. W., Patnaik, A., Shapiro, G., Chmielowski, B., Ribas, A., Brail, L. H., Roberts, J., Lee, L., O'Connell, B., Kutok, J. L., Mahabhashyam, S., Dansky Ullmann, C., Postow, M. A., & Wolchok, J. D.
Venue
Journal of Clinical Oncology
Published
2018-05-20
Volume
36
Issue
15_suppl
Pages
3013-3013
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2890904005
Cited by
58
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors. https://app.cochat.ai/papers/10.1200/jco.2018.36.15_suppl.3013
The paper
Sullivan, R. J., Hong, D. S., Tolcher, A. W., Patnaik, A., Shapiro, G., Chmielowski, B., Ribas, A., Brail, L. H., Roberts, J., Lee, L., O'Connell, B., Kutok, J. L., Mahabhashyam, S., Dansky Ullmann, C., Postow, M. A., & Wolchok, J. D. (2018). Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2018.36.15_suppl.3013

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.